MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
The SYNTAX Trial
Although percutaneous coronary intervention (PCI) for unprotected left main stenosis is a controversial subject today, it has a remarkably long history in the field of coronary intervention.
Percutaneous Mitral Valve Repair
An overview of the current devices and techniques.
By Raymond Leung, MDCM, and Ted Feldman, MD
Transcatheter Leaflet Repair for Functional MR
What will randomized trials mean for the future of mitral intervention?
By Ted Feldman, MD, FESC, FACC, MSCAI; Paul Sorajja, MD, FACC, FSCAI; Paul Grayburn, MD, FACC, FSCAI; and Francesco Maisano, MD
Safety and Durability Study of Evalve's MitraClip Published
August 11, 2009—In the Journal of the American College of Cardiology, Ted Feldman, MD, et al for the EVEREST investigators have published their safety and midterm durability findings of percutaneous mitral repair with the MitraClip system (Evalve Inc., Menlo Park, CA) in the initial cohort (2009;54:686–694).
Safety and Midterm Durability Study of Evalve's MitraClip Published
August 11, 2009—In the Journal of the American College of Cardiology, Ted Feldman, MD, et al for the EVEREST investigators have published their safety and midterm durability findings of percutaneous mitral repair with the MitraClip system (Evalve Inc., Menlo Park, CA) in the initial cohort (2009;54:686-694).
Results From the REDUCE LAP-HF I Trial Published
November 20, 2017—Thirty-day results from the REDUCE LAP-HF I trial were published online ahead of print by Ted Feldman, MD, et al in Circulation.
SCAI Publishes Structural Heart Disease Core Curriculum
September 13, 2010—The Society for Cardiovascular Angiography and Interventions (SCAI) announced the publication of a core curriculum consensus document for the treatment of structural heart disease, which was authored by Ted Feldman, MD, et al.
EVEREST II Data Support Abbott Vascular's MitraClip
May 25, 2010—Abbott Vascular (Santa Clara, CA) announced new data from the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) trial that were presented by coprincipal investigator Ted Feldman, MD, at the EuroPCR 2010 conference in Paris.
Two-Year EVEREST II Data Support Abbott Vascular's MitraClip
Evalve's MitraClip EVEREST Data Presented at TCT
September 22, 2009—Evalve, Inc. (Menlo Park, CA) announced that data were presented from the company's EVEREST (Endovascular Valve Edge-to-Edge Repair Study) registries studying reduction in mitral regurgitation (MR) at 12 months after percutaneous mitral valve repair with the MitraClip system.
EVEREST II
April 4, 2011—Abbott Vascular (Santa Clara, CA) announced data from its EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) study showing that patients with significant mitral regurgitation (MR) treated with the company's investigational percutaneous catheter–based MitraClip system continue to demonstrate the clinical benefits of initial treatment shown at 1 year out to 2 years, including improvements in heart function and reductions in symptoms.
One-Year Data Presented From REDUCE LAP-HF I Trial of Corvia Medical's IASD
August 27, 2018—Corvia Medical, Inc. announced 1-year follow-up data from the REDUCE LAP-HF I clinical study, which is evaluating the company’s transcatheter interatrial shunt device (IASD) for heart failure with preserved ejection fraction (HFpEF) and heart failure with mid-range ejection fraction (HFmrEF).
EVEREST II Presented for Abbott Vascular's MitraClip
March 14, 2010—Abbott Vascular (Santa Clara, CA) announced data from the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) trial demonstrated that the company's investigational MitraClip system met both its primary safety and effectiveness endpoints, suggesting that the MitraClip procedure may be an important treatment option for patients with significant mitral regurgitation (MR).
Two-Year EVEREST II Data Show Durable Clinical Benefits of Abbott's MitraClip System
EVEREST II Data Presented at ACC for Abbott Vascular's MitraClip System
Abbott to Acquire Evalve; MitraClip's EVEREST Data Presented at TCT
September 10, 2009—Abbott Vascular (Santa Clara, CA) announced a definitive agreement to acquire the outstanding equity of Evalve, Inc. (Menlo Park, CA).
FDA Approves Abbott Vascular's MitraClip
October 25, 2013—Abbott Vascular (Santa Clara, CA) announced that its catheter-based MitraClip therapy has received US Food and Drug Administration approval and will launch immediately in the United States.
An Interview With Timothy Sanborn, MD
Dr. Sanborn discusses his NorthShore facility, door-to-balloon time initiatives, and future developments in the field of cardiology.
Pivotal Trial Begins for Corvia Medical's IASD System for the Treatment of Heart Failure
November 14, 2017—Corvia Medical, Inc. announced that it has enrolled the first patients in its global, multicenter REDUCE LAP-HF II trial of the company's IASD interatrial shunt device system for the treatment of heart failure.
SCAI Comments on CMS MEDCAC Panel Regarding TAVR
July 26, 2018—The Society for Cardiovascular Angiography and Interventions (SCAI) released a statement commenting on the meeting of the Centers for Medicare & Medicaid Services (CMS) panel of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC), which was convened on July 25 to provide recommendations regarding procedural volume requirements for hospitals and heart team members to begin and maintain TAVR programs.
